Free Trial

ACADIA Pharmaceuticals (ACAD) Earnings Date, Estimates & Call Transcripts

ACADIA Pharmaceuticals logo
$16.87 +0.14 (+0.84%)
(As of 12/20/2024 05:15 PM ET)

ACADIA Pharmaceuticals Latest Earnings Summary

Actual EPS
(Nov. 6)
$0.20 Beat By $0.06
Consensus EPS
(Nov. 6)
$0.14

ACADIA Pharmaceuticals issued Q3 2024 earnings on November 6, 2024, reporting an EPS of $0.20, which topped the consensus estimate of $0.14 by $0.06. Quarterly revenue rose 18.3% year-over-year to $250.40 million, above analysts' expectations of $248.83 million. With a trailing EPS of $0.78 and a P/E Ratio of 21.63, ACADIA Pharmaceuticals' earnings are expected to grow 12.33% next year, from $0.73 to $0.82 per share.

Get ACADIA Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ACADIA Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

ACAD Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ACAD Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

ACADIA Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242-$0.01$0.12$0.06
Q2 20243$0.09$0.16$0.13
Q3 20243$0.08$0.22$0.17
Q4 20243$0.07$0.14$0.10
FY 202411$0.23$0.64$0.46
Q1 20251$0.14$0.14$0.14
Q2 20251$0.19$0.19$0.19
Q3 20251$0.20$0.20$0.20
Q4 20251$0.21$0.21$0.21
FY 20254$0.74$0.74$0.74
Q1 20261$0.19$0.19$0.19
Q2 20261$0.33$0.33$0.33
Q3 20261$0.38$0.38$0.38

ACADIA Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
11/6/2024Q3 2024$0.14$0.20+$0.06$0.20$248.83M$250.40M
8/6/2024Q2 2024$0.18$0.20+$0.02$0.20$235.95M$241.96M
5/8/2024Q1 2024$0.04$0.10+$0.06$0.10$208.31M$205.83M
2/27/2024Q4 2023$0.32$0.28 -$0.04$0.28$223.79M$231.04M
11/2/2023Q3 2023-$0.43-$0.40+$0.03-$0.40$194.40M$211.70M
8/2/2023Q2 2023-$0.12$0.01+$0.13$0.01$163.86M$165.20M
5/8/2023Q1 2023-$0.21-$0.27 -$0.06-$0.27$120.29M$118.46M
2/27/2023Q4 2022-$0.25-$0.26 -$0.01-$0.26$135.18M$136.49M

ACADIA Pharmaceuticals Earnings - Frequently Asked Questions

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earning data on Wednesday, November 6, 2024. Learn more on ACAD's earnings history.

ACADIA Pharmaceuticals updated its FY 2024 earnings guidance on Wednesday, November, 6th. The company issued revenue guidance of $940.0 million-$960.0 million, compared to the consensus revenue estimate of $952.5 million.

In the previous quarter, ACADIA Pharmaceuticals (NASDAQ:ACAD) reported $0.20 earnings per share (EPS) to beat the analysts' consensus estimate of $0.14 by $0.06. Learn more on analysts' earnings estimate vs. ACAD's actual earnings.

The conference call for ACADIA Pharmaceuticals's latest earnings report can be listened to online.
Listen to Conference Call

ACADIA Pharmaceuticals (NASDAQ:ACAD) has a recorded annual revenue of $929.24 million.

ACADIA Pharmaceuticals (NASDAQ:ACAD) has a recorded net income of -$61.29 million. ACAD has generated $0.78 earnings per share over the last four quarters.

ACADIA Pharmaceuticals (NASDAQ:ACAD) has a trailing price-to-earnings ratio of 21.63 and a forward price-to-earnings ratio of 23.11.

ACADIA Pharmaceuticals's earnings are expected to grow from $0.73 per share to $0.82 per share in the next year, which is a 12.33% increase.

More Earnings Resources from MarketBeat



This page (NASDAQ:ACAD) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners